rs761225832
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 0P and 6B. BP4_ModerateBS2
The NM_014467.3(SRPX2):c.161G>A(p.Arg54Gln) variant causes a missense, splice region change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000449 in 1,202,969 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 24 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. 14/22 in silico tools predict a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_014467.3 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -6 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SRPX2 | NM_014467.3 | c.161G>A | p.Arg54Gln | missense_variant, splice_region_variant | 3/11 | ENST00000373004.5 | NP_055282.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SRPX2 | ENST00000373004.5 | c.161G>A | p.Arg54Gln | missense_variant, splice_region_variant | 3/11 | 1 | NM_014467.3 | ENSP00000362095.3 |
Frequencies
GnomAD3 genomes AF: 0.00000898 AC: 1AN: 111387Hom.: 0 Cov.: 22 AF XY: 0.00 AC XY: 0AN XY: 33553
GnomAD3 exomes AF: 0.0000383 AC: 7AN: 182617Hom.: 0 AF XY: 0.0000596 AC XY: 4AN XY: 67107
GnomAD4 exome AF: 0.0000486 AC: 53AN: 1091582Hom.: 0 Cov.: 28 AF XY: 0.0000672 AC XY: 24AN XY: 357106
GnomAD4 genome AF: 0.00000898 AC: 1AN: 111387Hom.: 0 Cov.: 22 AF XY: 0.00 AC XY: 0AN XY: 33553
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 07, 2023 | The c.161G>A (p.R54Q) alteration is located in exon 3 (coding exon 2) of the SRPX2 gene. This alteration results from a G to A substitution at nucleotide position 161, causing the arginine (R) at amino acid position 54 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Rolandic epilepsy, intellectual disability, and speech dyspraxia, X-linked Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 15, 2021 | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The glutamine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. ClinVar contains an entry for this variant (Variation ID: 409283). This variant has not been reported in the literature in individuals affected with SRPX2-related conditions. This variant is present in population databases (rs761225832, gnomAD 0.02%). This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 54 of the SRPX2 protein (p.Arg54Gln). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at